Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder in geriatric people that characterized by reduction in memory and learning ability. Attenuation of cholinergic system is the most likely hypothesis. Therefore, potentiation of the cholinergic system via inhibition of acetylcholinesterase enzyme could improve and alleviate the symptoms of AD. A new series of isatin-based derivatives (4a-4h) were designed and synthesized according to the pharmacophore of donepezil and consequently related anti-cholinesterase effect was evaluated by Ellman's test. Obtained results were compared with donepezil as a standard drug. All of target derivatives (4a-4h) synthesized with moderate yields. In Ellman's test as an enzymatic assay for acetylcholinesterase, the most of them displayed better inhibitory potency in comparison with donepezil. In summary, isatin-based derivatives could be potential anti-Alzheimer agents. But, more experimental investigations are needed to prove this statement in the future.
Keywords
Copyright
© 2015, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.